Press Releases

Mark A. Goldberg, MD, Joins Intensity Therapeutics, Inc. Board of Directors

May 24 2018

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company’s Board of Directors effective May 1, 2018. Dr. Mark A. Goldberg recently served as president and COO of PAREXEL International, one of the world’s… Read more »

Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial

Feb 24 2018

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced completion of the first safety cohort (A) of the Company’s Phase 1/2 international clinical study evaluating lead product, INT230-6. Following intratumoral drug injections into superficial lesions in six patients with either ovarian, thyroid, head and… Read more »

Intensity Therapeutics Invited to Speak and Present at Upcoming Conferences

Feb 24 2018

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immune-based products, today announced that President and CEO Lewis H. Bender would be speaking on a CEO Panel titled: Raising Capital in the Current Market during the Immuno-Oncology 360° conference at the Roosevelt Hotel in New York City, NY February 7-9, 2018. IO360… Read more »

View All Press Releases